Table 1. Main clinicopathological parameters.
| Demographical and clinical characteristics | Overall | |
|---|---|---|
| 19 (100%) | ||
| Age at diagnostic | ||
| (years) | Median | 61.63 |
| Range | 43–78 | |
| Gender | Male | 16 (84%) |
| Female | 3 (16%) | |
| Histology | Superficial Spreading | 8 (42%) |
| Nodular | 5 (26%) | |
| Acral lentiginous | 2 (11%) | |
| Other | 4 (21%) | |
| Breslow (mm) | Median Range | 4.91 (0.35–10) |
| Assessed | 17 (89%) | |
| Numbers of metastatic sites before therapy | 1 | 8 (42%) |
| 2 | 5 (26%) | |
| 3 | 4 (21%) | |
| 4 | 2 (10%) | |
| Visceral disease | 15 (79%) | |
| Non visceral disease | 4 (21 (%) | |
| Brain metastasis | Yes | 3 (16%) |
| No | 16 (82%) | |
| Treatment | Targeted Therapy | 9 (47%) |
| BRAF inhibitors | 2 (10%) | |
| Combine MEK and BRAF inhibitors | 7 (36%) | |
| Immunotherapy | 9 (47%) | |
| anti-CTLA4 | 8 (42%) | |
| anti-PD1 | 1 (5%) | |
| Chemotherapy | 1 (5%) | |
| LDH | Assessed | 35 (100%) |
| Increased | 6 (17%) | |
| Range | 504–1826 | |
| Treatment line | 1 | 19 |
| Response at M2 | Complete response | 3 (16%) |
| Partial response | 5 (26%) | |
| Stabilization | 5 (26%) | |
| Progression | 6 (31%) | |
| Death before M2 | 2 (10%) | |
| Overall survival (month) | Median | 56.4 |
| Range | [28.0–NA] | |
| Mutational status in tumor tissue | BRAF | 10 (52%) |
| p.V600E | 9 | |
| p.V600K | 1 | |
| NRAS | 5 (26%) | |
| p.Q61K | 2 | |
| p.Q61L | 1 | |
| p.Q61R | 1 | |
| pG12S | 1 | |
| Double Wild-Type | 4 (21%) | |